About Roche Holding (VTX:ROG)
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Industry, Sector and Symbol
Industry Diversified Electronics
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Trailing EPSCHF 11.25
Return on Equity46.76%
Return on Assets14.96%
Frequently Asked Questions for Roche Holding (VTX:ROG)
What is Roche Holding's stock symbol?
Roche Holding trades on the VTX under the ticker symbol "ROG."
Where is Roche Holding's stock going? Where will Roche Holding's stock price be in 2017?
16 brokerages have issued 1 year target prices for Roche Holding's stock. Their forecasts range from CHF 205 to CHF 325. On average, they expect Roche Holding's stock price to reach CHF 265.56 in the next year. View Analyst Ratings for Roche Holding.
Who are some of Roche Holding's key competitors?
Some companies that are related to Roche Holding include Sanofi (SAN), Bayer AG (BAYN), CSL Limited (CSL), GlaxoSmithKline plc (GSK), AstraZeneca PLC (AZN), Aetna (AET), Anthem (ANTM), Covidien Ltd (COV), Regeneron Pharmaceuticals (REGN), Humana (HUM), Shire PLC (SHP), Essilor International Société Anonyme (EI), Agilent Technologies (A), Hospira (HSP), DENTSPLY SIRONA (XRAY), Ramsay Health Care Limited (RHC), Medivation (MDVN) and Catamaran Corp (CTRX).
Who are Roche Holding's key executives?
Roche Holding's management team includes the folowing people:
- Severin Schwan, Chairman of the Corporate Executive Committee, Chief Executive Officer, Executive Director (Age 50)
- Alan Hippe, Member of the Corporate Executive Committee, Chief Financial Officer, Information Technology Officer (Age 50)
- Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications (Age 55)
- Sophie Kornowski-Bonnet, Member of the Enlarged Corporate Executive Committee, Head Roche Partnering (Age 54)
- Osamu Nagayama, Member of the Enlarged Corporate Executive Committee, Chairman and Chief Executive Officer Chugai (Age 70)
- John C. Reed M.D., Ph.D., Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development (Age 59)
- Michael David Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development (Age 59)
- Cristina A. Wilbur, Member of the Executive Committee, Head Group Human Resources (Age 50)
- Urs Jaisli, Chief Compliance Officer (Age 61)
- Gottlieb A. Keller, Member of the Group Executive Committee, General Counsel, Secretary to the Board of Directors (Age 63)
What is Roche Holding's stock price today?
One share of Roche Holding stock can currently be purchased for approximately CHF 246.50.
How big of a company is Roche Holding?
Roche Holding has a market capitalization of $212.78 billion.
How can I contact Roche Holding?
Roche Holding's mailing address is Grenzacherstr. 124, BASEL, 4058, Switzerland. The healthcare company can be reached via phone at +41-9-732354295.
MarketBeat Community Rating for Roche Holding (ROG)MarketBeat's community ratings are surveys of what our community members think about Roche Holding and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Roche Holding (VTX:ROG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 7 Hold Ratings, 7 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.31)|
|Consensus Price Target: ||CHF 265.56|
Consensus Price Target History for Roche Holding (VTX:ROG)
Analysts' Ratings History for Roche Holding (VTX:ROG)
(Data available from 11/24/2015 forward)
|11/23/2017||Deutsche Bank AG||Set Price Target||Neutral||CHF 254|
|11/22/2017||Liberum Capital||Set Price Target||Buy||CHF 279|
|11/21/2017||Baader Bank||Set Price Target||Buy||CHF 256|
|11/21/2017||HSBC Holdings PLC||Set Price Target||Sell||CHF 205|
|11/20/2017||Berenberg Bank||Set Price Target||Neutral||CHF 260|
|11/20/2017||Goldman Sachs Group, Inc. (The)||Set Price Target||Buy||CHF 325|
|11/17/2017||Morgan Stanley||Set Price Target||Neutral||CHF 260|
|11/17/2017||J P Morgan Chase & Co||Reiterated Rating||Buy|
|11/16/2017||Jefferies Group LLC||Set Price Target||Buy||CHF 290|
|10/20/2017||Kepler Capital Markets||Set Price Target||Neutral||CHF 226|
|10/18/2017||Citigroup Inc.||Set Price Target||Neutral||CHF 255|
|10/16/2017||Credit Suisse Group||Set Price Target||Neutral||CHF 260|
|9/25/2017||BNP Paribas||Set Price Target||Sell||CHF 235|
|9/13/2017||Barclays PLC||Set Price Target||Buy||CHF 295|
|7/27/2017||Sanford C. Bernstein||Set Price Target||Buy||CHF 284|
|6/29/2017||Societe Generale||Set Price Target||Neutral||CHF 275|
Earnings History for Roche Holding (VTX:ROG)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Roche Holding (VTX:ROG)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Roche Holding (VTX:ROG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Roche Holding (VTX ROG)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Roche Holding (VTX ROG)
Financials are not available for this stock.